Stay updated on Risankizumab in PsA Patients: Clinical Trial
Sign up to get notified when there's something new on the Risankizumab in PsA Patients: Clinical Trial page.

Latest updates to the Risankizumab in PsA Patients: Clinical Trial page
- Check5 days agoNo Change Detected
- Check13 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.0%
- Check20 days agoChange DetectedThe page has undergone significant content removal, including the detailed description of a clinical study comparing risankizumab to placebo for psoriatic arthritis, along with its inclusion and exclusion criteria. The only notable addition is the mention of a new revision number.SummaryDifference6%
- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check41 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check63 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.5%
- Check89 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.5%
Stay in the know with updates to Risankizumab in PsA Patients: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Risankizumab in PsA Patients: Clinical Trial page.